Abbott Laboratories has a consensus price target of $136.59 based on the ratings of 22 analysts. The high is $150 issued by B of A Securities on March 10, 2025. The low is $120 issued by Freedom Broker on January 29, 2026. The 3 most-recent analyst ratings were released by Goldman Sachs, Barclays, and Evercore ISI Group on April 9, 2026, April 8, 2026, and April 6, 2026, respectively. With an average price target of $133 between Goldman Sachs, Barclays, and Evercore ISI Group, there's an implied 38.05% upside for Abbott Laboratories from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Abbott Laboratories (NYSE:ABT) was reported by Goldman Sachs on April 9, 2026. The analyst firm set a price target for $121.00 expecting ABT to rise to within 12 months (a possible 26.20% upside). 49 analyst firms have reported ratings in the last year.
The latest analyst rating for Abbott Laboratories (NYSE:ABT) was provided by Goldman Sachs, and Abbott Laboratories maintained their buy rating.
The last upgrade for Abbott Laboratories happened on January 29, 2026 when Freedom Broker raised their price target to $120. Freedom Broker previously had a hold for Abbott Laboratories.
There is no last downgrade for Abbott Laboratories.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abbott Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abbott Laboratories was filed on April 9, 2026 so you should expect the next rating to be made available sometime around April 9, 2027.
While ratings are subjective and will change, the latest Abbott Laboratories (ABT) rating was a maintained with a price target of $140.00 to $121.00. The current price Abbott Laboratories (ABT) is trading at is $95.88, which is out of the analyst’s predicted range.
